We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

62 hedge funds and large institutions have $66.3M invested in Lineage Cell Therapeutics in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

15% more capital invested

Capital invested by funds: $57.6M → $66.3M (+$8.69M)

7% more funds holding

Funds holding: 58 → 62 (+4)

4.98% more ownership

Funds ownership: 32.33% → 37.31% (+5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

98% less call options, than puts

Call options by funds: $4K | Put options by funds: $199K

Holders
62
Holders Change
+4
Holders Change %
+6.9%
% of All Funds
1.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
25
Reduced
11
Closed
6
Calls
$4K
Puts
$199K
Net Calls
-$195K
Net Calls Change
-$70K

Top Buyers

1
BC
Broadwood Capital
New York
+$10.1M
2
BFA
BlackRock Fund Advisors
California
+$556K
3
WSCM
Wellington Shields Capital Management
New York
+$410K
4
BIT
BlackRock Institutional Trust
California
+$286K
5
VKH
Virtu KCG Holdings
New York
+$133K

Top Sellers

1
CS
Credit Suisse
Switzerland
-$180K
2
Renaissance Technologies
Renaissance Technologies
New York
-$170K
3
Goldman Sachs
Goldman Sachs
New York
-$160K
4
Swiss National Bank
Swiss National Bank
Switzerland
-$93K
5
Deutsche Bank
Deutsche Bank
Germany
-$71.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$40.9M +$10.1M +4,460,444 +37%
BIT
2
BlackRock Institutional Trust
California
$5.38M +$286K +126,595 +6%
BFA
3
BlackRock Fund Advisors
California
$3.82M +$556K +246,132 +19%
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.71M +$54K +23,909 +2%
DWM
5
Destination Wealth Management
California
$1.81M – – –
State Street
6
State Street
Massachusetts
$1.55M +$4.23K +1,873 +0.3%
Northern Trust
7
Northern Trust
Illinois
$1.34M -$54.3K -24,051 -4%
Morgan Stanley
8
Morgan Stanley
New York
$770K -$12.3K -5,467 -2%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$609K +$40.9K +18,122 +8%
TCIM
10
TIAA CREF Investment Management
New York
$577K +$62.7K +27,763 +13%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$557K +$49K +21,693 +11%
BA
12
BlackRock Advisors
Delaware
$466K +$3.84K +1,701 +0.9%
BIM
13
BlackRock Investment Management
Delaware
$450K +$126K +55,895 +44%
WSCM
14
Wellington Shields Capital Management
New York
$447K +$410K +181,515 New
NFC
15
Northeast Financial Consultants
Connecticut
$385K – – –
BCM
16
Bridgeway Capital Management
Texas
$378K – – –
California State Teachers Retirement System (CalSTRS)
17
California State Teachers Retirement System (CalSTRS)
California
$290K +$79.5K +35,188 +43%
Charles Schwab
18
Charles Schwab
California
$255K +$90.9K +40,268 +64%
TA
19
Teachers Advisors
New York
$216K +$48K +21,236 +32%
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$180K – – –
D.E. Shaw & Co
21
D.E. Shaw & Co
New York
$154K +$3.11K +1,379 +2%
WJA
22
Williams Jones & Associates
New York
$153K – – –
VKH
23
Virtu KCG Holdings
New York
$145K +$133K +58,967 New
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$141K +$130K +57,364 New
AllianceBernstein
25
AllianceBernstein
Tennessee
$125K +$4.97K +2,203 +5%
1
2 3

LCTX Hedge Fund Activity: Q2 2014 in Review

62 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2014, worth a combined $66.3M — up 15% from $57.6M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new LCTX positions and 6 closed out — a net gain of 4 holders — while 25 added to existing stakes and 11 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $10.1M. The largest seller was Credit Suisse, cutting an estimated $180K.

  • 62 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2014, up from 58 in Q1 2014.
  • Funds reported $66.3M of Lineage Cell Therapeutics stock for Q2 2014, up 15% quarter-over-quarter.
  • 10 funds opened new Lineage Cell Therapeutics positions in Q2 2014 and 6 closed out, a net change of +4 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2014 was Broadwood Capital, an estimated $10.1M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2014 was Credit Suisse, an estimated $180K sold.

Based on aggregated 13F filings for Q2 2014.